Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pre-endoscopy coronavirus disease 2019 screening and severe acute respiratory syndrome coronavirus-2 nucleic acid amplification testing in the Veterans Affairs healthcare system: clinical practice patterns, outcomes, and relationship to procedure volume

Andrew J. Gawron, MD, PhD,1,2,3 Shahnaz Sultan, MD, MHSc,4 Thomas J. Glorioso, MS,5 Sophia Califano, MD, MPH,6,7 Stephen M. Kralovic, MD, MPH,8,9,10 Makoto Jones, MD,2,11 Susan Kirsh, MD, MPH,12 Jason A. Dominitz, MD, MHS1,13,14

Washington, DC; Salt Lake City, Utah; Minneapolis, Minnesota; Durham, North Carolina; Cincinnati, Ohio; Seattle, Washington, USA

Background and Aims: The coronavirus disease 2019 (COVID-19) pandemic has had profound impacts worldwide, including on the performance of GI endoscopy. We aimed to describe the performance and outcomes of pre-endoscopy COVID-19 symptom and exposure screening and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) nucleic acid amplification testing (NAAT) across the national Veterans Affairs healthcare system and describe the relationship of SARS-CoV-2 NAAT use and resumption of endoscopy services.

Methods: COVID-19 screening and NAAT results from March 2020 to April 2021 were analyzed to determine use, performance characteristics of screening, and association between testing and endoscopic volume trends.

Results: Of 220,891 completed endoscopies identified, 115,890 (52.5%) had documented preprocedure COVID-19 symptom and exposure screenings and 154,127 (69.8%) had preprocedure NAAT results within 7 days before scheduled endoscopy. Of 131,894 total canceled endoscopies, 26,475 (20.1%) had screening data and 28,505 (21.6%) had SARS-CoV-2 NAAT results. Overall, positive NAAT results were reported in 1.8% of all individuals tested and in 1.3% of those who screened negative. Among completed and canceled endoscopies, COVID-19 screening had a 34.6% sensitivity (95% confidence interval [CI], 32.4%-36.8%) and 96.4% specificity (95% CI, 96.2%-96.5%) when compared with NAAT. COVID-19 screening had a positive predictive value of 15.0% (95% CI, 14.0%-16.1%) and a negative predictive value of 98.7% (95% CI, 98.7%-98.8%). There was a very weak correlation between monthly testing and monthly endoscopy volume by site (Spearman rank correlation coefficient = .09).

Conclusions: These findings have important implications for decisions about preprocedure testing, especially given breakthrough infections among vaccinated individuals during the SARS-CoV-2 delta and omicron variant surge. (Gastrointest Endosc 2022;96:423-32.)
The coronavirus disease 2019 (COVID-19) pandemic has had a profound impact on elective procedures, including GI endoscopy. Early in the pandemic, the Veterans Health Administration acted quickly to cease all elective procedures, prioritizing the safety of veterans and staff, but this ultimately resulted in significant deferment of care. As the pandemic persisted, organizations, including the Veterans Health Administration, developed detailed guidance for resumption of care, including GI endoscopy. This guidance set minimum standards for infection control precautions (eg, personal protective equipment [PPE]) based on patient risk stratification and procedure risk (eg, aerosol generation). The protocols and recommendations developed in response to COVID-19 were based on rapidly evolving evidence and expert consensus. Key components of risk assessment for procedures included screening for presence of symptoms suggestive of COVID-19 (based on the Centers for Disease Control and Prevention guidance), risk of potential exposure to contacts with COVID-19, and, if available, pre-procedural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) nucleic acid amplification testing (NAAT).

Preprocedure testing guidance has evolved over the course of the pandemic. In July 2020, a rapid systematic review and guideline found that a pre-endoscopy testing strategy in asymptomatic individuals could be useful, depending on the local prevalence of the disease. In addition to helping with infection prevention and control, pre-endoscopy testing could provide reassurance to patients, staff, and endoscopists and inform decisions regarding PPE. The guidance also highlighted the downsides of a pre-endoscopy testing strategy, which included additional system, provider, and patient burden related to testing logistics. Updated guidance in May 2021, which preceded the current SARS-CoV-2 delta variant surge, included consideration of postvaccination status and conditional recommendations to cease routine SARS-CoV-2 testing before endoscopy as a systematic review found asymptomatic prevalence and transmission to be very low and assumed centers had adequate access to PPE and universal screening protocols.

The Veterans Health Administration comprises 170 medical facilities and 1074 outpatient sites serving over 6 million veterans annually, accounting for approximately 400,000 endoscopy visits annually before the pandemic. To ensure safe resumption of care during the pandemic, the Veterans Health Administration instituted a universal screening protocol for COVID-19 symptoms or exposure before permitting entry into medical facilities. Many endoscopy units implemented formal preprocedure screening via telephone (with documentation in the electronic health record) and SARS-CoV-2 NAAT before the endoscopy appointment.

As the largest integrated healthcare system in the United States, there is an opportunity to learn from the Veterans Health Administration’s nationwide experiences as the pandemic continues. The objectives of this evaluation are to describe the real-world results from a strategy of pre-endoscopy COVID-19 symptom and exposure screening and SARS-CoV-2 NAAT across the national Veterans Affairs (VA) healthcare system, including prevalence of asymptomatic infection among veterans undergoing endoscopy and the sensitivity and specificity of COVID-19 screening, and to geographically illustrate the use of pre-endoscopy SARS-CoV-2 NAAT and explore its association with endoscopy procedure volumes across the Veterans Health Administration.

**METHODS**

**Approvals**

The findings reported in this publication were conceived and conducted as a VA nonresearch operations activity. The results and report have been approved for submission as a nonresearch activity in accordance with VA Office of Research & Development Guide 1200.21.

**Data sources**

The Biosurveillance, Antimicrobial Stewardship & Infection Control program developed and validated a source code to evaluate pre-endoscopy SARS-CoV-2 NAAT results from the VA National Surveillance Tool housed within the VA Corporate Data Warehouse. The VA Clinical Assessment, Reporting, and Tracking program refined the code to extract outpatient VA endoscopies and SARS-CoV-2 NAAT results around procedure dates.

**Cohort definitions**

We included all veterans undergoing outpatient colonoscopy or EGD from March 18, 2020 through April 30, 2021 at any VA facility. These procedures were identified using Current Procedural Terminology codes (available online at www.giejournal.org) from administrative data. Because abnormal COVID-19 screening and/or NAAT results would likely result in canceled appointments, it was necessary to identify all canceled GI endoscopy appointments. Existing data systems do not permit determination of the reason for cancellation, such as abnormal NAAT, patient preference, or other reasons. To minimize cancellations for other reasons, we only included those endoscopy appointments that were canceled within 7 days of the scheduled appointment date because this corresponded to the timeframe of preprocedure screening and testing. Although most appointments in the endoscopy clinic are for colonoscopy or EGD, we could not definitively exclude appointments for other uncommon indications (eg, esophageal pH testing). VA uses 3-digit codes to classify outpatient specialty clinics, including endoscopy. However, some small facility sites perform endoscopy in the operating room. With these limitations in mind, we used the following 2 approaches to define canceled endoscopies because of COVID-19.

First, our primary (“inclusive”) approach aimed to optimize sensitivity at the risk of lower specificity. The
inclusive approach included all clinics that had at least 1 completed endoscopy within the clinic during calendar years 2019 to 2020 and either a clinic code for endoscopy assigned to the clinic or more than 50% of the completed visits within the clinic resulted in endoscopy.

Second, as part of a sensitivity analysis, a second (“conservative”) approach was used that likely captured fewer true endoscopy appointments (lower sensitivity) but reduced the number of false positives (higher specificity). The conservative approach only included clinic locations where 10% or more of the completed endoscopies at the facility occurred at the clinic and 75% or more of the completed visits at the clinic resulted in endoscopy.

**Pre-endoscopy COVID-19 screening**

Documentation of preprocedure COVID-19 symptom and exposure screening was identified using data generated from a nationally standardized COVID-19 screening tool implemented in the VA electronic health record (Supplementary Fig. 1, available online at www.giejournal.org). Text string searches were used to extract structured data correlating to the standard template that were then classified into categories for screen results (positive or negative), exposure (yes or no), travel (yes or no), flu (yes or no), cough (yes or no), and fever (yes or no). The “screen results” category was used to flag positive screens; however, if this information was not available, any “yes” response to exposure, travel, flu, cough, or fever was identified as a positive screen. Documentation of screening was restricted to 7 days before endoscopy. Screening the day of the procedure or before was considered screening before endoscopy. If multiple screening data were available during the pre-endoscopy period, any positive result was used first. Otherwise, the result closest to the date of the procedure was included in the analysis.

**SARS-CoV-2 NAAT results**

SARS-CoV-2 NAAT results are documented in the electronic health record and were collected from the testing datasets generated by the Biosurveillance, Antimicrobial Stewardship & Infection Control program from the VA Corporate Data Warehouse. Additionally, documentation of positive tests from the community were collected from clinical notes using natural language processing. Like screening, if multiple test results were available during the 7-day pre-endoscopy period, any positive result was used first, followed by the result closest to the procedure.

**Analyses and outcomes**

Descriptive and analytical statistics using R (version 4.0.3) were performed to determine the following findings:

- The overall and individual facility implementation and pre-endoscopy timing of COVID-19 screening and exposure and SARS-CoV-2 NAAT results.

**RESULTS**

**Implementation of preprocedure screening and testing**

Between March 18, 2020 and April 30, 2021, we identified 220,891 completed outpatient endoscopies at 118 VA facilities. Facility volume ranged from 76 to 7654 endoscopies over the 13.5-month time frame. Of the completed endoscopies, 115,890 (52.5%) had documented preprocedure COVID-19 symptom and exposure screening, and 154,127 (69.8%) had preprocedure SARS-CoV-2 NAAT results within 7 days before the procedure. In addition, 83,165 procedures (37.6%) had both documented preprocedure screening and testing, and 34,039 procedures (15.4%) had neither documented preprocedure screening nor testing. As shown in Figure 1, most (82.5%) preprocedure SARS-CoV-2 NAAT results were obtained within 3 days of the procedure, whereas screening was most commonly (58.0%) documented on the day of the procedure (day 0).

During the same time frame, we identified 26,475 canceled appointments with screening data and 28,505 canceled appointments with SARS-CoV-2 NAAT data out of 131,894 total canceled appointments (20.1% and 21.6%, respectively). There were 14,536 canceled appointments

![Figure 1. Timing of preprocedure coronavirus disease 2019 screening and severe acute respiratory syndrome coronavirus-2 NAAT results in completed endoscopies. Denominator for % calculation is total number of endoscopies with screening and NAAT performed, respectively; 47.5% of endoscopies did not have documented screening, whereas 50.2% of endoscopies did not have NAAT results. NAAT, Nucleic acid amplification testing.](image-url)
with both screening and SARS-CoV-2 NAAT data (11.0%). As shown in Figure 2, there was significant variation in the proportion of procedures with documented screening and SARS-CoV-2 NAAT results across VA facilities.

**Preprocedure screening and SARS-CoV-2 NAAT results in completed and canceled procedures**

Tables 1 and 2 show the overall results for COVID-19 screening and SARS-CoV-2 NAAT results in completed and canceled endoscopies. Of 115,890 completed procedures for which there were screening data, 1996 patients (1.7%) screened positive. Of 26,475 canceled endoscopies with screening data, 3029 patients (11.4%) screened positive. Of 154,127 completed procedures with SARS-CoV-2 NAAT results, 413 patients (.3%) had positive NAAT results. These 413 positive SARS-CoV-2 tests using NAAT occurred across 90 sites, and the remaining 28 sites had no positive tests pre-endoscopy. Of 28,505 canceled endoscopies with SARS-CoV-2 NAAT data, 2878 patients (10.1%) were NAAT positive. Among the 2878 canceled endoscopies with positive SARS-CoV-2 NAAT results, 588 patients (20.4%) had documented positive screening, 980 (34.1%) had documented negative screening, and 1310 (45.5%) did not have screening documented.

Figure 3 shows the monthly pre-endoscopy NAAT volume (completed and canceled procedures combined) and positive NAAT per month. Only 37 pre-endoscopy tests were performed in March 2020, followed by an increase in testing volume over the following months. Testing volume reached a peak in March 2021 with 21,136 NAAT performed pre-endoscopy. Excluding March 2020 data, the proportion of positive NAAT results per month ranged from .5% in June 2020 to a high of 3.7% in January 2021. The proportion of positive tests per month increased through January 2021 with a subsequent decline in April 2021 to 1.4%.

Using SARS-CoV-2 NAAT results as the reference standard, we estimated the performance of preprocedure

---

**Table 1. COVID-19 screening and SARS-CoV-2 NAAT results in completed endoscopies, March 2020 to April 2021**

|                | SARS-CoV-2 NAAT results |     |     |     |     |
|----------------|-------------------------|-----|-----|-----|-----|
|                | Positive | Negative | Missing | Total |
| COVID-19 screening | 31 | 1652 | 313 | 1996 |
| Row % | 1.6 | 82.8 | 15.7 |
| Column % | 7.5 | 1.1 | .5 |
| Negative | 191 | 81,291 | 32,412 | 113,894 |
| Row % | .2 | 71.4 | 28.5 |
| Column % | 46.2 | 52.9 | 48.5 |
| Missing | 191 | 70,771 | 34,039 | 105,001 |
| Row % | .2 | 67.4 | 32.4 |
| Column % | 46.2 | 46.0 | 51.0 |
| Total | 413 | 153,714 | 66,764 | 220,891 |

COVID-19, Coronavirus disease 2019; NAAT, nucleic acid amplification testing; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.
screening using data from all canceled and completed endoscopies for which there was both screening and polymerase chain reaction data (Table 3). Positive NAAT results were reported in 1.8% of all individuals tested and in 1.3% of those who screened negative. Among those patients who had positive SARS-CoV-2 NAAT results, 34.6% also screened positive for COVID-19 (ie, screening sensitivity, 34.6%; 95% confidence interval [CI], 32.4%-36.8%). The specificity of screening was 96.4% (95% CI, 96.2%-96.5%). Conversely, among those patients with positive COVID-19 screening, 15.0% had a positive NAAT result (screening positive predictive value, 15.0%; 95% CI, 14.0%-16.1%). The negative predictive value of screening was 98.7% (95% CI, 98.7%-98.8%). Using the conservative definition of canceled endoscopies did not appreciably change these results, with 429 NAAT-positive patients screening positive (32.9% of 1303 patients with NAAT-positive results). The NAAT positivity rate in screen-positive patients using the conservative definition was 13.6% (429 NAAT positive of 3154 patients who screened positive).

A sensitivity analysis limited to the sites in the top 50% with the least missing data for both screening and NAAT results included 91,494 (25.9% of the primary cohort) completed or canceled appointments at 30 sites. The sensitivity analysis cohort for completed endoscopies had a missing rate of 17% for screening data and 5% for NAAT results compared with 48% and 48%, respectively, in the primary cohort. When considering completed and canceled endoscopy appointments combined, screening data were missing in 38% and NAAT results were missing in 29% compared with 60% and 48%, respectively, in the primary cohort. No clinically significant change was found in the

### Table 2. COVID-19 screening and SARS-CoV-2 NAAT results in canceled endoscopies (using inclusive definition of canceled endoscopies)

|                  | Positive | Negative | Missing | Total |
|------------------|----------|----------|---------|-------|
| COVID-19 screening |          |          |         |       |
| Positive         | 588      | 1842     | 599     | 3029  |
| Row %            | 19.4     | 60.8     | 19.8    |       |
| Column %         | 20.4     | 7.2      | .6      |       |
| Negative         | 980      | 11,126   | 11,340  | 23,446|
| Row %            | 4.2      | 47.5     | 48.4    |       |
| Column %         | 34.1     | 43.4     | 11.0    |       |
| Missing          | 1310     | 12,659   | 91,450  | 105,419|
| Row %            | 1.2      | 12.0     | 86.7    |       |
| Column %         | 45.5     | 49.4     | 88.5    |       |
| Total            | 2878     | 25,627   | 103,389 | 131,894|

COVID-19, Coronavirus disease 2019; NAAT, nucleic acid amplification testing; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.
test performance results or proportion of patients with negative or positive screening or NAAT results in the top 50% of sites with the least missing screening and NAAT results (Supplementary Tables 1 and 2, available online at www.giejournal.org).

Geographic and facility endoscopy volume compared with proportion of patients with pre-endoscopy SARS-CoV-2 NAAT

The average 30-day endoscopy volume was determined in relation to the proportion of patients with preprocedure SARS-CoV-2 testing in completed endoscopies. Figure 4 shows geographic information system trend maps to visualize endoscopy volume and the proportion of patients tested over time. By December 2020, most endoscopy sites used SARS-CoV-2 NAAT before endoscopy. There was a very weak correlation between monthly testing and monthly endoscopy volume by site across the Veterans Health Administration using a within-cluster re-sampling approach (Spearman rank correlation coefficient = .09) (Supplementary Fig. 2, available online at www.giejournal.org). Using data on completed procedures through April 2021, 71 sites (60.2%) completed testing in 80% to 100% of procedures, accounting for 120,891 total procedures (54.8% of 220,891 total procedures performed). During the same time frame, 17 sites (14.4%) were testing 0% to 20% of individuals pre-endoscopy, accounting for 32,002 total procedures (14.5% of total procedures performed) across the VA system.

DISCUSSION

The COVID-19 pandemic required swift adaptations in healthcare delivery in the United States and globally. Although rapid growth in telemedicine mitigated negative effects for many specialties, procedure-based specialties, such as GI endoscopy, were significantly impacted. This report describes the use of preprocedure COVID-19 symptom screening and viral testing before endoscopy, the outcomes of a pretesting strategy, and the temporal relationship with endoscopy volumes within the largest integrated healthcare system in the United States.

First and foremost, our data reveal remarkably rapid uptake of documented pre-endoscopy COVID-19 screening and viral testing across the VA healthcare system through April 2021. Screening was mandated by the VA and occurred at each facility entrance, although this screening was not documented in the electronic health record. Therefore, our data reflect additional pre-endoscopy screening that was documented in the electronic health record. Preprocedure testing was not mandated nationally, with local leadership providing risk assessment guidance for facilities. In individuals scheduled for elective endoscopy, this approach can reduce potential exposure to infection for staff and other patients. Screening for symptoms or exposures alone adds value, because those patients who screened positive had a 15.0% NAAT positivity rate. However, screening alone would have missed 65.4% of individuals found to have SARS-CoV-2 infection among those who had both SARS-CoV-2 NAAT and screening data reported.

Our data from over 300,000 procedure appointments show the uptake of preprocedure testing and documented screening as the pandemic spread across the United States. This likely helps explain our NAAT positivity rate of 15.0% in screen-positive patients, much higher than previously reported early in the pandemic. Two cost-effectiveness studies on pre-endoscopy testing and PPE use found that routine pre-endoscopy testing was more cost effective as the prevalence of COVID-19 increased. Overall, 1.3% of endoscopy patients with negative screening tested positive for SARS-CoV-2, similar to an observational study recently reported from the Netherlands evaluating pre-endoscopy screening and testing before elective surgery. Data early in the pandemic on pre-endoscopy SARS-CoV-2 testing and screening showed similarly high negative predictive value for symptom screening but low positive predictive

### TABLE 3. COVID-19 screening and SARS-CoV-2 NAAT results in completed and canceled endoscopies (inclusive definition) and COVID-19 screening test performance*

| COVID-19 screening | Positive | Negative | Total |
|--------------------|----------|----------|-------|
|                     |          |          |       |
| Row %               |          |          |       |
| Column %            |          |          |       |
| Positive            | 619      | 3494     | 4113  |
| Negative            | 1171     | 92,417   | 93,588|
| Total               | 1790     | 95,911   | 97,701|

*Excluding veterans with missing data on screening or NAAT results.

**COVID-19**, Coronavirus disease 2019; **NAAT**, nucleic acid amplification testing; **SARS-CoV-2**, severe acute respiratory syndrome coronavirus-2.
value. These published studies were from single centers and reported results from the first few months of the pandemic (March to May 2020). Notably, another recent study reported on preprocedural SARS-CoV-2 testing at 5 academic hospitals and 19 community hospitals in Pennsylvania and New York during 3 different phases of the pandemic. The prevalence of asymptomatic COVID-19 among individuals undergoing pre-endoscopy testing was .10% (10/10,539) from April 21 to June 11, 2020, .15% (54/34,948) from June 12 to September 10, 2020, and .41% (101/24,741) from September 11 to December 15, 2020. Our inclusion of patients with canceled appointments is important because failure to do so would underestimate the prevalence of COVID-19 infection in patients undergoing endoscopy in the absence of preprocedure testing. Of the procedures that were canceled in the VA system, 4.0% of patients with canceled procedures either had abnormal COVID-19 screening or NAAT results. Thus, we can only attribute cancellations to COVID-19 disease in a very small percentage of scheduled endoscopies.

Our results from the VA provide important information about the discriminative value of preprocedure COVID-19 screening and SARS-CoV-2 NAAT that can be used to optimize preprocedure protocols for endoscopy as the pandemic continues, driven by SARS-CoV-2 variants and variable vaccination status of patients across the country. The VA guidance provided detailed guidance on screening, testing, and PPE recommendations. For GI endoscopy, the guidance recommended N95 masks with eye protection or a powered air purifying respirator (PAPR) irrespective of COVID-19 test status. If COVID-19 status was unknown, then the procedure room could not be used for another patient until enough air exchange occurred to meet infection prevention rules for downtime to clear the virus. This VA guidance likely helped encourage sites to adopt preprocedure testing. The variability in reported testing between sites could be due to a variety of reasons, such as test availability or local testing policy. There is also variability in the proportion of patients with documented screening. However, even if a preprocedural phone call was not performed or documented, any patient reporting symptoms or exposure would not be permitted entry to a VA facility except to receive care specific to that symptom or exposure. It is possible that VA requirements for symptom and exposure screening for entry into its facilities may have decreased the perceived importance of screening before arrival.

We hypothesized that facilities with greater access to NAAT may have been able to offer more endoscopic services. However, our results did not reveal evidence to support a meaningful correlation between endoscopy volume and use of pre-endoscopy NAAT. Multiple factors likely played a role in resuming endoscopy volume, including pre-endoscopy testing. We were also unable to measure staff availability, PPE availability, local leadership decisions regarding endoscopy services, and COVID-19 burden at individual sites. Preprocedural SARS-CoV-2 testing, although recommended, is not mandatory in VA sites. Variation in practice patterns may have been influenced by local factors including local COVID-19 epidemiology, NAAT availability,
Before returning to near-baseline levels in late 2020 (Supplementary Fig. 3, available online at www.giejournal.org). Although we were unable to determine an exact reason for cancellation in most cases, the 4% cancellation rate attributed to COVID-19 represents a floor because others may have canceled because of COVID-19 concerns that were not reported. Next, we may have underestimated the use of pre-endoscopy SARS-CoV-2 NAAT if testing occurred outside of the VA. We only examined COVID-19 tests within 7 days of the procedure and did not measure or include NAAT done more than 7 days pre-endoscopy. NAAT performed before this time frame may have impacted clinical decision-making and added to the reasons for procedure cancellation. However, the overall U.S. population rate for COVID-19 remained at less than 5% of the population during this time and would likely have had little overall effect on cancellation rates in our study.32 Finally, missing data on screening and NAAT could be nonrandom, leading to biased conclusions. It is reassuring that a sensitivity analysis that was restricted to 30 sites with the least missing data yielded very similar results.

This report has several strengths including a very large sample size spanning endoscopy centers that are geographically distributed throughout the United States, accounting for variability in COVID-19 prevalence across the nation and throughout the first 13.5 months of the pandemic. Furthermore, the inclusion of screening and testing data from canceled appointments is critical to estimating the impact on endoscopy services. The presence of varying practices regarding SARS-CoV-2 screening and testing, where testing policies are determined at the local level based on local risk analysis, illustrates generalizability and real-world applicability. Although practice settings differ within and outside the Veterans Health Administration, most healthcare systems have the ability to incorporate intake or preprocedure COVID-19 screening analogous to intake protocols that assess medication use and nil per os (NPO) status. SARS-CoV-2 testing availability does depend on local resources, including widespread availability of rapid antigen tests as an option for consideration.

In summary, we describe the results of pre-endoscopy COVID-19 screening and SARS-CoV-2 NAAT use in the VA healthcare system during the first 13.5 months of the pandemic. Numerous questions and areas of future study remain, including those surrounding unintended consequences related to pretesting requirements before receiving endoscopy care. For example, postponement of endoscopy may lead to poor patient outcomes, such as delayed cancer diagnoses.3,33 Emergence of variant strains of the virus, such as delta and omicron, with decreased vaccine efficacy and asymptomatic transmission, has prolonged the course of the pandemic, necessitating careful evaluation of the role of screening and testing practices. Our findings can help inform decisions regarding the role of pre-endoscopy screening and testing. In fact, newly updated guidance
from the American Society of Anesthesiologists recommend that all patients undergoing an aerosolizing procedure (such as EGD) should continue to have preoperative polymerase chain reaction testing for SAR-CoV-2, ideally within 3 days of the procedure, irrespective of vaccination status. Any perceived decrease in safe practices in endoscopy centers may lead to heightened anxiety among patients and staff, which could also negatively impact patients’ willingness to undergo endoscopy and/or staff morale and performance. This report illustrates 1 of many adaptations made within the VA as a learning healthcare system that seeks to continually generate and apply evidence and innovation to provide high-quality care during an unprecedented time as we continue into the second, and hopefully final, year of the COVID-19 pandemic.

ACKNOWLEDGMENT

The contents of this work do not represent the views of the Department of Veterans Affairs or the U.S. Government.

Funding/Support: This work was supported by the Veterans Health Administration. Role of the Funder/Sponsor: The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

1. Das A. Impact of the COVID-19 pandemic on the workflow of an ambulatory endoscopy center: an assessment by discrete event simulation. Gastrointest Endosc 2020;92:914-24.
2. Gawron AJ, Kaltenbach T, Dominitz JA. The impact of the coronavirus disease-19 pandemic on access to endoscopy procedures in the VA Healthcare System. Gastroenterology 2020;159:1216-20.
3. Balzora S, Issaka RB, Anyane-Yeboa A, et al. Impact of COVID-19 on colorectal cancer disparities and the way forward. Gastrointest Endosc 2020;92:946-50.
4. Castro Filho EC, Castro R, Fernandes FF, et al. Gastrointestinal endoscopy during the COVID-19 pandemic: an updated review of guidelines and statements from international and national societies. Gastrointest Endosc 2020;92:440-5.
5. Veterans Health Administration. Moving forward guidebook: safe care is our mission. 2020. Available at: https://www.va.gov/covidtraining/docs/20200611/MovingForward/VHA_Moving_Foward_Guidebook.pdf. Accessed January 18, 2022.
6. Veterans Health Administration. COVID-19: guidance for elective gastroenterology and hepatology procedures. 2020. Available at: https://govsolutions.sharepoint.com/wc/w/sites/VACOHAPublicHealth/HCI/Moving%20Forward/Moving%20Forward%20Plan%2019122020-09172020%20-%20Moving%20Forward%20Guidance%20for%20Resumption%20of%20Procedures%20for%20Non-urgent%20and%20Elective%20Indications_2.0_FINAL.docx. Accessed May 20, 2022.
7. Han J, Wang Y, Zhu L, et al. Preventing the spread of COVID-19 in digestive endoscopy during the resuming period: meticulous execution of screening procedures. Gastrointest Endosc 2020;92:445-7.
8. Guidance for COVID-19. Volume 2020. Centers for Disease Control and Prevention. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/community/guidance-list.html?Sort=Date%3A%3A%3A&Audience=Healthcare%20Professionals. Accessed January 10, 2022.
9. Sultan S, Siddique SM, Altayar O, et al. AGA Institute rapid review and recommendations on the role of pre-procedure SARS-CoV-2 testing and endoscopy. Gastroenterology 2020;159:1935-48.
10. Mahadev S, Aroniadis OC, Barraza LH, et al. Gastrointestinal endoscopy during the coronavirus pandemic in the New York area: results from a multi-institutional survey. Endosc Int Open 2020;8:E1865-71.
11. Rex DK, Vemulpalapli KC, Kane MJ, et al. Most patients are willing to undergo elective endoscopic procedures during the reopening period of the coronavirus 2019 pandemic. Gastroenterology 2020;159:1173-5.
12. Rex DK, Vemulpalapli KC, Lahr RE, et al. Endoscopy staff are concerned about acquiring coronavirus disease 2019 infection when resuming elective endoscopy. Gastroenterology 2020;159:1167-9.
13. Podboy A, Cholankeril G, Gianfichi L, et al. Implementation and impact of universal preprocedure testing of patients for COVID-19 before endoscopy. Gastroenterology 2020;159:1586-8.
14. Sultan S, Siddique SM, Singh S, et al. AGA rapid review and guideline for SARS-CoV2 testing and endoscopy post vaccination: 2021 update. Gastroenterology 2021;161:1011-29.
15. Department of Veterans Affairs. Veterans Health Administration. Available at: https://www.va.gov/health/aboutVHA.asp. Accessed January 10, 2022.
16. Department of Veterans Affairs, Office of Research & Development Program Guide: 1200.21, 2019 Available at: https://www.research.va.gov/resources/policies/ProgramGuide-1200-21-VHA-Operations-Activities.pdf. Accessed January 10, 2022.
17. National Surveillance Tool assesses readiness across VA’s health system. Vantage Point. 2020. Published May 21, 2020. Available at: https://blogs.va.gov/vantage/74896/national-surveillance-tool-assesses-readiness-across-vas-health-system/. Accessed January 18, 2022.
18. Department of Veterans Affairs. VHA directive 1158: clinical assessment reporting and tracking program for invasive cardiac procedures. Available at: https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=8229. Accessed January 18, 2022.
19. Harris AH, Reeder RN, Ellerbe L, et al. Are VHA administrative location codes valid indicators of specialty substance use disorder treatment? J Rehabil Res Dev 2010;47:699-708.
20. Chapman A, Peterson K, Turano A, et al. A natural language processing system for national COVID-19 surveillance in the US Department of Veterans Affairs. Proceedings of the 1st Workshop on NLP for COVID-19 at ACL 2020. ACL Anthology. 2020. Available at: https://aclanthology.org/2020.nlpcovid19-1a.10/. Accessed January 18, 2022.
21. Shih JH, Fay MP. Pearson’s chi-square test and rank correlation inferences for clustered data. Biometrics 2017;73:822-34.
22. Albaroia M, Piscoya A, Tran QT, et al. Global impact of COVID-19 on gastrointestinal endoscopy units: an international survey of endoscopists. Arab J Gastroenterol 2020;21:156-61.
23. Lui TKL, Leung K, Guo CG, et al. Impacts of the coronavirus 2019 pandemic on gastrointestinal endoscopy volume and diagnosis of gastric and colorectal cancers: a population-based study. Gastroenterology 2020;159:1164-6.
24. Timmouth J, Dong S, Stogios C, et al. Estimating the backlog of colonoscopy due to coronavirus disease 2019 and comparing strategies to recover in Ontario, Canada. Gastroenterology 2021;160:1400-2.
25. Elbigio A, Römmele C, Bartenschlager C, et al. Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment. Endoscopy 2021;53:156-61.
26. Deckert A, Anders S, de Allegri M, et al. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Trials 2021;22:39.
27. Puylaert CAJ, Scheijmans JCG, Borgstein ABJ, et al. Yield of screening for COVID-19 in asymptomatic patients before elective or emergency
surgery using chest CT and RT-PCR (SCOUT): multicenter study. Ann Surg 2020;272:919-24.

28. Bowyer B, Thukral C, Patel S, et al. Outcomes of symptom screening and universal COVID-19 reverse transcriptase polymerase chain reaction testing before endoscopy in a community-based ambulatory surgery center. Gastrointest Endosc 2020;93:1060-4.

29. Dolinger MT, Kumta NA, Greenwald DA, et al. Outcomes of universal preprocedure coronavirus disease 2019 testing before endoscopy in a tertiary care center in New York City. Gastroenterology 2020;159:1962-4.

30. Forde JJ, Goldberg D, Sussman D, et al. Yield and implications of preprocedural COVID-19 polymerase chain reaction testing on routine endoscopic practice. Gastroenterology 2020;159:1538-40.

31. Haidar G, Ayres A, King WC, et al. Preprocedural SARS-CoV-2 testing to sustain medically needed health care delivery during the COVID-19 pandemic: a prospective observational study. Open Forum Infect Dis 2021;8:ofab022.

32. Centers for Disease Control and Prevention. COVID data tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#trends_totalcases. Accessed January 11, 2022.

33. Gupta S, Lieberman D. Screening and surveillance colonoscopy and COVID-19: avoiding more casualties. Gastroenterology 2020;159:1205-8.

34. American Society of Anesthesiologists. American Society of Anesthesiologists and the anesthesia patient safety foundation statement on perioperative testing for the COVID-19 virus. August 2021. Available at: https://www.asahq.org/about-asa/newsroom/news-releases/2021/08/asa-and-apsf-statement-on-perioperative-testing-for-the-covid-19-virus. Accessed January 11, 2022.

Abbreviations: COVID-19, coronavirus disease 2019; NAAT, nucleic acid amplification testing; PPE, personal protective equipment; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; VA, Veterans Affairs.

DISCLOSURE: All authors disclosed no financial relationships.

Copyright © 2022 by the American Society for Gastrointestinal Endoscopy

0016-5107/$36.00
https://doi.org/10.1016/j.gie.2022.04.018

Received August 27, 2021. Accepted April 12, 2022.

Current affiliations: National Gastroenterology and Hepatology Program (1), National Infectious Diseases Service (8), Office of Specialty Care Services, Department of Veterans Affairs, Washington, DC, USA; VA Salt Lake City Health Care System, Salt Lake City, Utah, USA (2), Division of Gastroenterology (3), Division of Epidemiology (11), University of Utah School of Medicine, Salt Lake City, Utah, USA; Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis VAHCS, Minneapolis, Minnesota, USA (4), CART Program, Office of Quality and Patient Safety (5), Preventive Medicine, National Center for Health Promotion and Disease Prevention (6), Office of Veterans Access to Care (12), Veterans Health Administration, Washington, DC, USA; General Internal Medicine, Duke University, Durham, North Carolina, USA (7), Medical Service, Cincinnati VA Medical Center, Cincinnati, Ohio, USA (9), Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA (10), VA Puget Sound Health Care System, Seattle, Washington, USA (13), Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington, USA (14).

Reprint requests: Jason A. Dominitz, MD, MHS, VA Puget Sound Health Care System, Seattle Division (111-S-Gastro), 1660 S Columbian Way, Seattle, WA 98108.

If you would like to chat with an author of this article, you may contact Dr. Dominitz at dominitz@u.washington.edu.
### Current Procedural Terminology (CPT) codes used to identify endoscopies in the VA healthcare System

| CPTCODE | DESCRIPTION |
|---------|-------------|
| G9937   | DIAGNOSTIC COLONOSCOPY |
| G9936   | SURVEILLANCE COLONOSCOPY - PERSONAL HISTORY OF COLOIC POLYPS, COLON CANCER, OR OTHER MALIGNANT NEOPLASM OF RECTUM, RECTOSIGMOID JUNCTION, AND ANUS |
| G0121   | COLORECTAL CANCER SCREENING; COLONOSCOPY ON INDIVIDUAL NOT MEETING CRITERIA FOR HIGH RISK |
| G0105   | COLORECTAL CANCER SCREENING; COLONOSCOPY ON INDIVIDUAL AT HIGH RISK |
| 74328   | ENDOSCOPIC CATHETERIZATION OF THE BILIARY DUCTAL SYSTEM, RADIOLOGICAL SUPERVISION AND INTERPRETATION |
| 45398   | COLONOSCOPY, FLEXIBLE; WITH DECOMPRESSION (FOR PATHOLOGIC DISTENTION) (EG, VOLVULUS, MEGACOLON), INCLUDING PLACEMENT OF DECOMPRESSION TUBE, WHEN PERFORMED |
| 45393   | COLONOSCOPY, FLEXIBLE; WITH TRANSENDOSCOPIC ULTRASOUND GUIDED INTRAMURAL OR TRANSMURAL FINE NEEDLE ASPIRATION/BIOPSY(S), INCLUDES ENDOSCOPIC ULTRASOUND EXAMINATION LIMITED TO THE RECTUM, SIGMOID, DESCENDING, TRANSVERSE, OR ASCENDING COLON AND CECUM, AND ADJACENT STRUCTURES |
| 45392   | COLONOSCOPY, FLEXIBLE; WITH TRANSENDOSCOPIC ULTRASOUND GUIDED INTRAMURAL OR TRANSMURAL FINE NEEDLE ASPIRATION/BIOPSY(S), INCLUDES ENDOSCOPIC ULTRASOUND EXAMINATION LIMITED TO THE RECTUM, SIGMOID, DESCENDING, TRANSVERSE, OR ASCENDING COLON AND CECUM, AND ADJACENT STRUCTURES |
| 45391   | COLONOSCOPY, FLEXIBLE; WITH ENDOSCOPIC ULTRASOUND EXAMINATION LIMITED TO THE RECTUM, SIGMOID, DESCENDING, TRANSVERSE, OR ASCENDING COLON AND CECUM, AND ADJACENT STRUCTURES |
| 45390   | COLONOSCOPY, FLEXIBLE; WITH ENDOSCOPIC MUCOSAL RESECTION |
| 45389   | COLONOSCOPY, FLEXIBLE; WITH ENDOSCOPIC STENT PLACEMENT (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED) |
| 45388   | COLONOSCOPY, FLEXIBLE; WITH ABLATION OF TUMOR(S), POLYP(S), OR OTHER LESION(S) (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED) |
| 45386   | COLONOSCOPY, FLEXIBLE; WITH TRANSENDOSCOPIC BALLOON DILATION |
| 45385   | COLONOSCOPY, FLEXIBLE; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY SNARE TECHNIQUE |
| 45384   | COLONOSCOPY, FLEXIBLE; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY HOT BIOPSY FORCEPS |
| 45382   | COLONOSCOPY, FLEXIBLE; WITH CONTROL OF BLEEDING, ANY METHOD |
| 45381   | COLONOSCOPY, FLEXIBLE; WITH DIRECTED SUBMUCOSAL INJECTION(S), ANY SUBSTANCE |
| 45380   | COLONOSCOPY, FLEXIBLE; WITH BIOPSY, SINGLE OR MULTIPLE |
| 45379   | COLONOSCOPY, FLEXIBLE; WITH REMOVAL OF FOREIGN BODY(S) |
| 45378   | COLONOSCOPY, FLEXIBLE; DIAGNOSTIC, INCLUDING COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING, WHEN PERFORMED (SEPARATE PROCEDURE) |
| 45350   | SIGMOIDOSCOPY, FLEXIBLE; WITH BAND LIGATION(S) (EG, HEMORRHoids) |
| 45349   | SIGMOIDOSCOPY, FLEXIBLE; WITH ENDOSCOPIC MUCOSAL RESECTION |
| 45347   | SIGMOIDOSCOPY, FLEXIBLE; WITH PLACEMENT OF ENDOSCOPIC STENT (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED) |
| 45346   | SIGMOIDOSCOPY, FLEXIBLE; WITH ABLATION OF TUMOR(S), POLYP(S), OR OTHER LESION(S) (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED) |
| 45342   | SIGMOIDOSCOPY, FLEXIBLE; WITH TRANSENDOSCOPIC ULTRASOUND GUIDED INTRAMURAL OR TRANSMURAL FINE NEEDLE ASPIRATION/BIOPSY(S) |
| 45341   | SIGMOIDOSCOPY, FLEXIBLE; WITH ENDOSCOPIC ULTRASOUND EXAMINATION |
| 45340   | SIGMOIDOSCOPY, FLEXIBLE; WITH TRANSENDOSCOPIC BALLOON DILATION |
| 45338   | SIGMOIDOSCOPY, FLEXIBLE; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY SNARE TECHNIQUE |
| 45337   | SIGMOIDOSCOPY, FLEXIBLE; WITH DECOMPRESSION OF VOLVULUS, ANY METHOD |
| 45335   | SIGMOIDOSCOPY, FLEXIBLE; WITH DIRECTED SUBMUCOSAL INJECTION(S), ANY SUBSTANCE |
| 45334   | SIGMOIDOSCOPY, FLEXIBLE; WITH CONTROL OF BLEEDING, ANY METHOD |
| 45333   | SIGMOIDOSCOPY, FLEXIBLE; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY HOT BIOPSY FORCEPS |
| 45332   | SIGMOIDOSCOPY, FLEXIBLE; WITH REMOVAL OF FOREIGN BODY(S) |
| 45331   | SIGMOIDOSCOPY, FLEXIBLE; WITH BIOPSY, SINGLE OR MULTIPLE |

(continued on the next page)
| CPT CODE | DESCRIPTION |
|----------|-------------|
| 45330    | SIGMOIDOSCOPY, FLEXIBLE; DIAGNOSTIC, WITH OR WITHOUT COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING (SEPARATE PROCEDURE) |
| 44404    | COLONOSCOPY THROUGH STOMA; WITH DIRECTED SUBMUCOSAL INJECTION(S), ANY SUBSTANCE |
| 44403    | COLONOSCOPY THROUGH STOMA; WITH ENDOSCOPIC MUCOSAL RESECTION |
| 44401    | COLONOSCOPY THROUGH STOMA; WITH ABLATION OF TUMOR(S), POLYP(S), OR OTHER LESION(S) (INCLUDES PRE-AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED) |
| 44394    | COLONOSCOPY THROUGH STOMA; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY SNARE TECHNIQUE |
| 44392    | COLONOSCOPY THROUGH STOMA; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY HOT BIOPSY FORCEPS OR BIPOLAR CAUTERY |
| 44391    | COLONOSCOPY THROUGH STOMA; WITH CONTROL OF BLEEDING, ANY METHOD |
| 44389    | COLONOSCOPY THROUGH STOMA; WITH BIOPSY, SINGLE OR MULTIPLE |
| 44388    | ENDOSCOPIC EVALUATION OF SMALL INTESTINAL POUCH (EG, KOCK POUCH, ILEAL RESERVOIR [S OR J]); WITH BIOPSY, SINGLE OR MULTIPLE |
| 44386    | ENDOSCOPIC EVALUATION OF SMALL INTESTINAL POUCH (EG, KOCK POUCH, ILEAL RESERVOIR [S OR J]); DIAGNOSTIC, INCLUDING COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING, WHEN PERFORMED (SEPARATE PROCEDURE) |
| 44384    | ILEOSCOPY, THROUGH STOMA; WITH PLACEMENT OF ENDOSCOPIC STENT (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED) |
| 44382    | ILEOSCOPY, THROUGH STOMA; WITH BIOPSY, SINGLE OR MULTIPLE |
| 44381    | ILEOSCOPY, THROUGH STOMA; WITH TRANSENDOSCOPIC BALLOON DILATION |
| 44380    | ILEOSCOPY, THROUGH STOMA; DIAGNOSTIC, WITH OR WITHOUT COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING (SEPARATE PROCEDURE) |
| 44378    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, INCLUDING ILEUM; WITH CONTROL OF BLEEDING (EG, INJECTION, BIPOLAR CAUTERY, UNIPOLAR CAUTERY, LASER, HEATER PROBE, STAPLER, PLASMA COAGULATOR) |
| 44377    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, INCLUDING ILEUM; WITH BIOPSY, SINGLE OR MULTIPLE |
| 44376    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, INCLUDING ILEUM; DIAGNOSTIC, WITH OR WITHOUT COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING (SEPARATE PROCEDURE) |
| 44373    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; WITH CONVERSION OF PERCUTANEOUS GASTROSTOMY TUBE TO PERCUTANEOUS JEJUNOSTOMY TUBE |
| 44372    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; WITH PLACEMENT OF PERCUTANEOUS JEJUNOSTOMY TUBE |
| 44370    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; WITH TRANSENDOSCOPIC STENT PLACEMENT (INCLUDES PREDILATION) |
| 44369    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; WITH ABLATION OF TUMOR(S), POLYP(S), OR OTHER LESION(S) NOT AMENABLE TO REMOVAL BY HOT BIOPSY FORCEPS, BIPOLAR CAUTERY OR SNARE TECHNIQUE |
| 44366    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; WITH CONTROL OF BLEEDING (EG, INJECTION, BIPOLAR CAUTERY, UNIPOLAR CAUTERY, LASER, HEATER PROBE, STAPLER, PLASMA COAGULATOR) |
| 44365    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY HOT BIOPSY FORCEPS OR BIPOLAR CAUTERY |
| 44364    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY SNARE TECHNIQUE |
| 44363    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; DIAGNOSTIC, INCLUDING COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING, WHEN PERFORMED (SEPARATE PROCEDURE) |
| 44361    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; WITH BIOPSY, SINGLE OR MULTIPLE |
| 44360    | SMALL INTESTINAL ENDOSCOPY, ENTEROSCOPY BEYOND SECOND PORTION OF DUODENUM, NOT INCLUDING ILEUM; DIAGNOSTIC, INCLUDING COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING, WHEN PERFORMED (SEPARATE PROCEDURE) |

(continued on the next page)
43278  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH ABLATION OF TUMOR(S), POLYP(S), OR OTHER LESION(S), INCLUDING PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED

43277  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH TRANS-ENDOSCOPIC BALLOON DILATION OF BILIARY/pancreatic duct(s) OR OF AMPULLA (SPHINCTEROLPLASTY), INCLUDING SPHINCTEROTOMY, WHEN PERFORMED, EACH DUCT

43276  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH REMOVAL AND EXCHANGE OF STENT(S), BILIARY OR PANCREATIC DUCT, INCLUDING PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED, INCLUDING SPHINCTEROTOMY, WHEN PERFORMED, EACH STENT EXCHANGED

43275  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH REMOVAL OF FOREIGN BODY(S) OR STENT(S) FROM BILIARY/PANCREATIC DUCT(S)

43274  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH PLACEMENT OF ENDOSCOPIC STENT INTO BILIARY OR PANCREATIC DUCT, INCLUDING PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED, INCLUDING SPHINCTEROTOMY, WHEN PERFORMED, EACH STENT

43270  ESOPHAGOGASTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH ABLATION OF TUMOR(S), POLYP(S), OR OTHER LESION(S) (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED)

43266  ESOPHAGOGASTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH PLACEMENT OF ENDOSCOPIC STENT (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED)

43265  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH ENDOSCOPIC RETROGRADE DESTRUCTION, LITHOTRIPSY OF CALCULUS/CALCULI, ANY METHOD

43264  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH REMOVAL OF CALCULI/DEBRIS FROM BILIARY/PANCREATIC DUCT(S)

43262  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH SPHINCTEROTOMY/PAPILLOTOMY

43261  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); WITH BIOPSY, SINGLE OR MULTIPLE

43260  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP); DIAGNOSTIC, WITH OR WITHOUT COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING (SEPARATE PROCEDURE)

43259  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH ENDOSCOPIC ULTRASOUND EXAMINATION, INCLUDING THE ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE

43257  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH DELIVERY OF THERMAL ENERGY TO THE MUSCLE OF LOWER ESOPHAGEAL SPHINCTER AND/OR GASTRIC CARDIA, FOR TREATMENT OF GASTROESOPHAGEAL REFUX DISEASE

43255  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH CONTROL OF BLEEDING, ANY METHOD

43254  ESOPHAGOGASTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH ENDOSCOPIC MUCOSAL RESECTION

43253  ESOPHAGOGASTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH TRANSENDOSCOPIC ULTRASOUND-GUIDED TRANSMURAL INJECTION OF DIAGNOSTIC OR THERAPEUTIC SUBSTANCE(S) (EG, ANESTHETIC, NEUROLYTIC AGENT) OR FIDUCIAL MARKER(S) (INCLUDES ENDOSCOPIC ULTRASOUND EXAMINATION OF THE ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM OR A SURGICALLY ALTERED STOMACH WHERE THE JEJUNUM IS EXAMINED DISTAL TO THE ANASTOMOSIS)

43252  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH OPTICAL ENDOMICROSCOPY

43251  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY SNARE TECHNIQUE

43250  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY HOT BIOPSY FORCEPS OR BIPOLAR CAUTERY

43249  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH BALLOON DILATION OF ESOPHAGUS (LESS THAN 30 MM DIAMETER)

43248  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH INSERTION OF GUIDE WIRE FOLLOWED BY DILATION OF ESOPHAGUS OVER GUIDE WIRE

43247  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH REMOVAL OF FOREIGN BODY

43246  UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH DIRECTED PLACEMENT OF PERCUTANEOUS GASTROSTOMY TUBE

(continued on the next page)
| CPT CODE | DESCRIPTION |
|----------|-------------|
| 43245    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH DILATION OF GASTRIC OUTLET FOR OBSTRUCTION (EG, BALLOON, GUIDE WIRE, BOUGIE) |
| 43244    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH BAND LIGATION OF ESOPHAGEAL AND/OR GASTRIC VARICES |
| 43243    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH INJECTION SCLEROSIS OF ESOPHAGEAL AND/OR GASTRIC VARICES |
| 43242    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH TRANSENDOSCOPIC ULTRASOUND-GUIDED INTRAMURAL OR TRANSMURAL FINE NEEDLE ASPIRATION/BIOPSY(S) (INCLUDES ENDOCOPIC ULTRASOUND EXAMINATION OF THE ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE) |
| 43241    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH TRANSENDOSCOPIC INTRALUMINAL TUBE OR CATHETER PLACEMENT |
| 43240    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH TRANSMURAL DRAINAGE OF PSEUDOCYST |
| 43239    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH BIOPSY, SINGLE OR MULTIPLE |
| 43238    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH TRANSENDOSCOPIC ULTRASOUND-GUIDED INTRAMURAL OR TRANSMURAL FINE NEEDLE ASPIRATION/BIOPSY(S), ESOPHAGUS (INCLUDES ENDOCOPIC ULTRASOUND EXAMINATION LIMITED TO THE ESOPHAGUS) |
| 43237    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH ENDOCOPIC ULTRASOUND EXAMINATION LIMITED TO THE ESOPHAGUS |
| 43236    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH DIRECTED SUBMUCOSAL INJECTION(S), ANY SUBSTANCE |
| 43235    | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; DIAGNOSTIC, WITH OR WITHOUT COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING (SEPARATE PROCEDURE) |
| 43233    | ESOPHAGOSTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH DILATION OF ESOPHAGUS WITH BALLOON (30 MM DIAMETER OR LARGER) (INCLUDES FLUOROSCOPIC GUIDANCE, WHEN PERFORMED) |
| 43232    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH TRANSENDOSCOPIC ULTRASOUND-GUIDED INTRAMURAL OR TRANSMURAL FINE NEEDLE ASPIRATION/BIOPSY(S) |
| 43231    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH ENDOCOPIC ULTRASOUND EXAMINATION |
| 43229    | ESOPHAGOSCOPY, FLEXIBLE, TRANSORAL; WITH ABLATION OF TUMOR(S), POLYP(S), OR OTHER LESION(S) (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED) |
| 43227    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH CONTROL OF BLEEDING (EG, INJECTION, BIPOLAR CAUTERY, UNIPOLAR CAUTERY, LASER, HEATER PROBE, STAPLER, PLASMA COAGULATOR) |
| 43226    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH INSERTION OF GUIDE WIRE FOLLOWED BY DILATION OVER GUIDE WIRE |
| 43220    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH BALLOON DILATION (LESS THAN 30 MM DIAMETER) |
| 43217    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH REMOVAL OF TUMOR(S), POLYP(S), OR OTHER LESION(S) BY SNARE TECHNIQUE |
| 43215    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH REMOVAL OF FOREIGN BODY |
| 43214    | ESOPHAGOSCOPY, FLEXIBLE, TRANSORAL; WITH DILATION OF ESOPHAGUS WITH BALLOON (30 MM DIAMETER OR LARGER) (INCLUDES FLUOROSCOPIC GUIDANCE, WHEN PERFORMED) |
| 43213    | ESOPHAGOSCOPY, FLEXIBLE, TRANSORAL; WITH DILATION OF ESOPHAGUS, BY BALLOON OR DILATOR, RETROGRADE (INCLUDES FLUOROSCOPIC GUIDANCE, WHEN PERFORMED) |
| 43212    | ESOPHAGOSCOPY, FLEXIBLE, TRANSORAL; WITH PLACEMENT OF ENDOCOPIC STENT (INCLUDES PRE- AND POST-DILATION AND GUIDE WIRE PASSAGE, WHEN PERFORMED) |
| 43211    | ESOPHAGOSCOPY, FLEXIBLE, TRANSORAL; WITH ENDOCOPIC MUCOSAL RESECTION |
| 43210    | ESOPHAGOGASTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH ESOPHAGOGASTRIC FUNDOPERSONOPHY, PARTIAL OR COMPLETE, INCLUDES DUODENOSCOPY WHEN PERFORMED |
| 43206    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH OPTICAL ENDOMICROSCOPY |
| 43205    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH BAND LIGATION OF ESOPHAGEAL VARICES |
| 43204    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH INJECTION SCLEROSIS OF ESOPHAGEAL VARICES |
| 43202    | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH BIOPSY, SINGLE OR MULTIPLE |

(continued on the next page)
Continued

| CPTCODE | DESCRIPTION |
|---------|-------------|
| 43201   | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; WITH DIRECTED SUBMUCOSAL INJECTION(S), ANY SUBSTANCE |
| 43200   | ESOPHAGOSCOPY, RIGID OR FLEXIBLE; DIAGNOSTIC, WITH OR WITHOUT COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING (SEPARATE PROCEDURE) |
| 43198   | ESOPHAGOSCOPY, FLEXIBLE, TRANSNASAL; WITH BIOPSY, SINGLE OR MULTIPLE |
| 43197   | ESOPHAGOSCOPY, FLEXIBLE, TRANSNASAL; DIAGNOSTIC, INCLUDING COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING, WHEN PERFORMED (SEPARATE PROCEDURE) |

VA Coronavirus Disease 2019 (COVID-19) Screen – Reminder dialog template

- Complete COVID-19 Screen
  - Record the patient’s response to the following question: (check all that apply or none at the end)
  - In the last 14 days have you had new onset of any of the following symptoms?
    - Chills
    - Cough
    - Diarrhea
    - Fatigue
    - Fever
    - Headache
    - Loss of taste or smell
    - Muscle pain (myalgias)
    - Nausea
    - Runny nose (rhinorrhea)
    - Shortness of breath (dyspnea)
    - Sore throat
    - Vomiting
    - No symptoms
  - Within the last 14 days, you had:
    - Close exposure (within 6 feet for more than 15 minutes) to someone with a febrile/respiratory illness
    - Close exposure (within 6 feet for more than 15 minutes) to someone with known or suspected case of COVID-19
    - No known exposure
  - Any symptom or exposure equal to positive screen
    - Patient has a positive symptom or exposure and requires further evaluation
    - Screen in negative

- Patient is waiting on COVID-19 test results
- Patient reports prior COVID-19 Diagnosis
- Unable to answer

**Supplementary Figure 1.** Screenshot of VA COVID-19 screening tool in the electronic health record. VA, Veterans Affairs.
**Supplementary Figure 2.** Correlation plot between monthly nucleic acid amplification testing use and monthly endoscopy volume by site using a within-cluster-resampling approach. COVID, Coronavirus disease 2019; PCR, polymerase chain reaction.

**Supplementary Figure 3.** Veterans Affairs endoscopy appointment cancellation rate from January 2019 to April 2021.
### SUPPLEMENTARY TABLE 1. Coronavirus disease 2019 screening performance compared with NAAT for the primary cohort and a subpopulation of the top 50% of sites with least missing screening and NAAT data (including both completed and canceled [inclusive definition] endoscopy appointments)

|                                | Primary cohort results | Top 50% sites with least missing data |
|--------------------------------|------------------------|--------------------------------------|
| No. of records                 | 352,785                | 91,494                               |
| No. of sites                   | 118                    | 30                                   |
| No. with screening and NAAT data | 97,701                 | 52,932                               |
| Screening sensitivity, %       | .35 (.32-.37)          | .33 (.30-.37)                        |
| Screening specificity, %       | .96 (.96-.97)          | .98 (.97-98)                         |
| Screening positive predictive value, % | .15 (.14-.16) | .17 (.16-.19)                        |
| Screening negative predictive value, % | .99 (.98-.99) | .99 (.99-99)                         |

Values in parentheses are 95% confidence intervals. NAAT, Nucleic acid amplification testing.

### SUPPLEMENTARY TABLE 2. COVID-19 screening and SARS-CoV-2 NAAT results in completed and canceled endoscopies (inclusive definition) and COVID-19 screening test performance*

|                                | SARS-CoV-2 NAAT results |
|--------------------------------|-------------------------|
|                                | Primary analysis cohort | Sensitivity analysis cohort |
| Screening                      | Positive | Negative | Total | Positive | Negative | Total |
| Positive                       | 619      | 3494     | 4113  | 250      | 1185     | 1435  |
| Row %                          | 15       | 85       | 17.4  | 17.4     | 82.6     | 92.6  |
| Column %                       | 34.6     | 3.6      | 33.3  | 3.3      | 99.7     | 99.7  |
| Negative                       | 1171     | 92,417   | 93,588| 500      | 50,997   | 51,497| 51,497 |
| Row %                          | 1.3      | 98.7     | 1.0   | 1.0      | 99.0     | 99.0  |
| Column %                       | 65.4     | 96.4     | 66.7  | 97.7     | 97.7     | 97.7  |
| Total                          | 1790     | 95,911   | 97,701| 750      | 52,182   | 52,932| 52,932 |

Sensitivity analysis cohort is limited to sites in the top 50% with least missing screening and NAAT data. COVID-19, Coronavirus disease 2019; NAAT, nucleic acid amplification testing; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.

*Excluding veterans with missing data on screening or NAAT results.